title: Long term results of cyclophosphamide, adriamycin and platinum chemotherapy in advanced epithelial ovarian cancer.
abstract: Between January 1980 and December 1983, 57 consecutive patients with advanced epithelial ovarian cancer (FIGO Stage IIc n = 5; III n = 45; IV n = 7) were treated with 6 cycles of cyclophosphamide 600 mg/m2, adriamycin 30-45 mg/m2 and platinum 50 mg/m2 (CAP) at 3 weekly intervals. Pathological complete remission (CR) was documented in 10 (18%) and 4 with no residual disease after primary cytoreductive surgery were free from progression (FFP). There were 19 partial remissions (PR) giving a 51% overall response rate. The median duration of CR was 33 months from second look surgery. Median survival (MS) for all patients was 22 months. Multivariate analysis indicated that response to chemotherapy was the most important prognostic factor, with MS for CR of 53 months, PR 23 months and stable or progressive disease 11 months (p = 0.001). Most CR (8 of 10) occurred in patients with minimal residual disease (no single lesion greater than 2.0 cm), but extent of disease, though significant in univariate analysis of prognostic factors was not an independent predictor of survival. Six patients (11%) are alive and tumour free with a minimum follow-up of 7 years. All had FIGO Stage III disease at presentation and four had no residual tumour after primary surgery.
authors.affiliation: Department of Medical Oncology, Western Infirmary, Glasgow, U.K.
authors.forename: M
authors.initials: M
authors.lastname: Harding
authors.forename: R
authors.initials: R
authors.lastname: Milsted
authors.forename: D
authors.initials: D
authors.lastname: Hole
authors.forename: J
authors.initials: J
authors.lastname: Cordiner
authors.forename: W
authors.initials: W
authors.lastname: Barr
authors.forename: M
authors.initials: M
authors.lastname: Soukop
authors.forename: J
authors.initials: J
authors.lastname: Kennedy
authors.forename: W P
authors.initials: WP
authors.lastname: Soutter
authors.forename: S
authors.initials: S
authors.lastname: Kaye
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D010984:Platinum / Q000008:administration & dosage; D011379:Prognosis; D012074:Remission Induction; D016019:Survival Analysis
chemical_list: D010984:Platinum; D004317:Doxorubicin; D003520:Cyclophosphamide